MAPT and Alzheimer disease: The objective of this study was to explore whether predefined AD core plasma biomarkers (i.e., Aβ42/Aβ40 ratio, pTau181) and neuronal injury biomarkers (NFL, total tau) may provide clinical significance in the diagnosis, staging, and cognitive prediction of patients with TCP.